Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash from Investing Activities (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Cash from Investing Activities data on record, last reported at -$34.2 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 198.0% year-over-year to -$34.2 million; the TTM value through Dec 2025 reached -$30.3 million, down 204.97%, while the annual FY2025 figure was -$30.3 million, 204.97% down from the prior year.
  • Cash from Investing Activities reached -$34.2 million in Q4 2025 per ARQT's latest filing, down from -$25.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $107.8 million in Q1 2023 and bottomed at -$197.3 million in Q3 2022.
  • Average Cash from Investing Activities over 5 years is $782350.0, with a median of $16.4 million recorded in 2022.
  • Peak YoY movement for Cash from Investing Activities: plummeted 5783.15% in 2022, then skyrocketed 604.39% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at $23.5 million in 2021, then soared by 79.59% to $42.2 million in 2022, then tumbled by 247.36% to -$62.2 million in 2023, then surged by 156.08% to $34.9 million in 2024, then tumbled by 198.0% to -$34.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$34.2 million in Q4 2025, -$25.2 million in Q3 2025, and $17.4 million in Q2 2025.